Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years

NCT03883204 is registered in ClinicalTrials.gov with Fundación Marques de Valdecilla as lead sponsor.

NCT NCT03883204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03883204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole and Risperidone Over 3 Years
Lead sponsor
Fundación Marques de Valdecilla
Phase
Phase 4
Overall status
Unknown status
Start date
January 1, 2015
Completion date
December 31, 2020
Enrollment
115 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis, psychotic disorders, schizophrenia